Owlstone Medical Ltd

Life Sciences

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

  • Sector Life Sciences
  • Moved in 2015
  • Staff 130

Owlstone Medical has developed Breath Biopsy®, a non-invasive way to measure chemicals in breath, for disease detection, exposure monitoring, and drug metabolism. Owlstone Medical’s mission is to save 100,000 lives and $1.5B in health care costs.

Owlstone Medical is currently involved in the world’s largest breath-based lung cancer trial, called LuCID, which will recruit 4000 patients over its duration as it looks for biomarkers with to assist with early detection of lung cancer. The company also combines its products and services offering to collaborate with academic, clinical and pharma partners who want to develop breath-based diagnostics for their own applications.

The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.

Visit website

Owlstone Medical discoveries and awards

2018 2016
  • 2018

    MacRobert Award - Winner Royal Academy of Engineering Award

    Owlstone Medical's ReCIVA Breath Sampler wins the prestigious MacRobert Award. The ReCIVA Breath Sampler, part of the Breath Biopsy® platform, has opened up the potential for earlier diagnosis and precision medicine across cancer, inflammatory disease and infectious disease.

  • 2017

    Business Innovation Award - Winner Cambridge News & Media Business Excellence Awards

    Owlstone Medical wins the Business Innovation Award for its Breath Biopsy® technology in the Cambridge News & Media Business Excellence Awards.

  • 2017

    Royal Academy of Engineering - Silver Medal Winner Royal Academy of Engineering Awards

    Owlstone Medical CEO Billy Boyle is awarded the prestigious Silver Medal in recognition of pioneering work spearheading the development of the company’s Breath Biopsy® platform.

  • 2016

    Life Science Innovation Award - winners Business Weekly

    Owlstone Medical headed off fierce competition to take the AstraZeneca/MedImmune Life Science Innovation Award.

Contact us

Thank you for your enquiry!
We'll be in touch soon.

We couldn't send your message.
Please review the fields then try again